These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 31111400)
1. Network Patterns of Beta-Amyloid Deposition in Parkinson's Disease. Kim J; Ghadery C; Cho SS; Mihaescu A; Christopher L; Valli M; Houle S; Strafella AP Mol Neurobiol; 2019 Nov; 56(11):7731-7740. PubMed ID: 31111400 [TBL] [Abstract][Full Text] [Related]
2. Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Petrou M; Dwamena BA; Foerster BR; MacEachern MP; Bohnen NI; Müller ML; Albin RL; Frey KA Mov Disord; 2015 Jun; 30(7):928-35. PubMed ID: 25879534 [TBL] [Abstract][Full Text] [Related]
3. Differences in Aβ brain networks in Alzheimer's disease and healthy controls. Duan H; Jiang J; Xu J; Zhou H; Huang Z; Yu Z; Yan Z; Brain Res; 2017 Jan; 1655():77-89. PubMed ID: 27867033 [TBL] [Abstract][Full Text] [Related]
4. Use of T1-weighted/T2-weighted magnetic resonance ratio to elucidate changes due to amyloid β accumulation in cognitively normal subjects. Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Takahashi M; Nakagawara J; Iida H; Kishimoto T; Nagatsuka K Neuroimage Clin; 2017; 13():209-214. PubMed ID: 28003959 [TBL] [Abstract][Full Text] [Related]
5. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. Klunk WE; Lopresti BJ; Ikonomovic MD; Lefterov IM; Koldamova RP; Abrahamson EE; Debnath ML; Holt DP; Huang GF; Shao L; DeKosky ST; Price JC; Mathis CA J Neurosci; 2005 Nov; 25(46):10598-606. PubMed ID: 16291932 [TBL] [Abstract][Full Text] [Related]
6. Serotonin, β-amyloid, and cognition in Parkinson disease. Kotagal V; Spino C; Bohnen NI; Koeppe R; Albin RL Ann Neurol; 2018 May; 83(5):994-1002. PubMed ID: 29665066 [TBL] [Abstract][Full Text] [Related]
7. The Interaction Between Neuroinflammation and β-Amyloid in Cognitive Decline in Parkinson's Disease. Ghadery C; Koshimori Y; Christopher L; Kim J; Rusjan P; Lang AE; Houle S; Strafella AP Mol Neurobiol; 2020 Jan; 57(1):492-501. PubMed ID: 31385228 [TBL] [Abstract][Full Text] [Related]
10. In vivo SPECT imaging of amyloid-β deposition with radioiodinated imidazo[1,2-a]pyridine derivative DRM106 in a mouse model of Alzheimer's disease. Chen CJ; Bando K; Ashino H; Taguchi K; Shiraishi H; Shima K; Fujimoto O; Kitamura C; Matsushima S; Uchida K; Nakahara Y; Kasahara H; Minamizawa T; Jiang C; Zhang MR; Ono M; Tokunaga M; Suhara T; Higuchi M; Yamada K; Ji B J Nucl Med; 2015 Jan; 56(1):120-6. PubMed ID: 25476539 [TBL] [Abstract][Full Text] [Related]
11. Striatal and Cortical β-Amyloidopathy and Cognition in Parkinson's Disease. Shah N; Frey KA; Müller ML; Petrou M; Kotagal V; Koeppe RA; Scott PJ; Albin RL; Bohnen NI Mov Disord; 2016 Jan; 31(1):111-7. PubMed ID: 26380951 [TBL] [Abstract][Full Text] [Related]
12. Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals. Schultz AP; Chhatwal JP; Hedden T; Mormino EC; Hanseeuw BJ; Sepulcre J; Huijbers W; LaPoint M; Buckley RF; Johnson KA; Sperling RA J Neurosci; 2017 Apr; 37(16):4323-4331. PubMed ID: 28314821 [TBL] [Abstract][Full Text] [Related]
14. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Villemagne VL; Ataka S; Mizuno T; Brooks WS; Wada Y; Kondo M; Jones G; Watanabe Y; Mulligan R; Nakagawa M; Miki T; Shimada H; O'Keefe GJ; Masters CL; Mori H; Rowe CC Arch Neurol; 2009 Dec; 66(12):1537-44. PubMed ID: 20008660 [TBL] [Abstract][Full Text] [Related]
15. Amyloid β accumulation assessed with ¹¹C-Pittsburgh compound B PET and postmortem neuropathology. Hatsuta H; Takao M; Ishii K; Ishiwata K; Saito Y; Kanemaru K; Arai T; Suhara T; Shimada H; Shinotoh H; Tamaoka A; Murayama S Curr Alzheimer Res; 2015; 12(3):278-86. PubMed ID: 25731622 [TBL] [Abstract][Full Text] [Related]
16. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition. Park JC; Han SH; Cho HJ; Byun MS; Yi D; Choe YM; Kang S; Jung ES; Won SJ; Kim EH; Kim YK; Lee DY; Mook-Jung I Alzheimers Res Ther; 2017 Mar; 9(1):20. PubMed ID: 28330509 [TBL] [Abstract][Full Text] [Related]